Cover Image
Read Now

HPV testing for primary cervical cancer screening recommendations report

CADTH undertook a Health Technology Assessment (HTA) to inform policy decisions through a review of the evidence relating to clinical effectiveness and safety, cost-effectiveness, patients' perspectives and experiences, ethical issues, and implementation issues regarding the use of HPV versus c...

Full description

Bibliographic Details
Corporate Author: Canadian Agency for Drugs and Technologies in Health
Format: eBook
Language:English
Published: Ottawa (ON) CADTH March 2019, 2019
Series:CADTH optimal use report
Subjects:
Canada
Liquid Biopsy
Uterine Cervical Neoplasms / Diagnosis
Papanicolaou Test
Outcome Assessment, Health Care
Human Papillomavirus Dna Tests
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
Description
Summary:CADTH undertook a Health Technology Assessment (HTA) to inform policy decisions through a review of the evidence relating to clinical effectiveness and safety, cost-effectiveness, patients' perspectives and experiences, ethical issues, and implementation issues regarding the use of HPV versus cytology-based primary cervical cancer screening programs. The HTA informed the following policy questions: Should HPV testing replace cervical cytology in Canadian jurisdictions as the primary screening tool for cervical cancer? If yes, what criteria, including appropriate screening interval and ages to start and stop screening, should guide HPV-based cervical cancer screening programs in Canada?
Physical Description:1 PDF file (22 pages) illustrations

Similar Items